BTC $70614.7035
ETH $3511.7004
BNB $620.2579
SOL $173.0218
XRP $0.6097
stETH $3507.5030
DOGE $0.1974
TON $7.0340
ADA $0.5814
AVAX $46.2782
wstETH $4079.6154
DOT $8.3856
BCH $610.3232
WETH $3506.2796
WBTC $70620.3107
TRX $0.1214
LINK $17.6767
MATIC $0.8810
UNI $9.1130
LTC $98.3227
ICP $15.5376
CAKE $3.7378
DAI $0.9997
IMX $2.5624
ETC $33.6826
RNDR $9.0476
STX $3.0152
FIL $8.0739
MNT $1.3057
TAO $634.6650
NEAR $6.7707
HBAR $0.0996
ATOM $10.7689
VET $0.0473
OKB $56.7850
WIF $3.4067
FDUSD $1.0024
KAS $0.1425
MKR $3339.9801
PEPE $0.0000
GRT $0.3118
THETA $2.9461
INJ $31.7489
FET $2.5268
XLM $0.1299
XMR $133.8901
USDE $1.0008
BTC $70614.7035
ETH $3511.7004
BNB $620.2579
SOL $173.0218
XRP $0.6097
stETH $3507.5030
DOGE $0.1974
TON $7.0340
ADA $0.5814
AVAX $46.2782
wstETH $4079.6154
DOT $8.3856
BCH $610.3232
WETH $3506.2796
WBTC $70620.3107
TRX $0.1214
LINK $17.6767
MATIC $0.8810
UNI $9.1130
LTC $98.3227
ICP $15.5376
CAKE $3.7378
DAI $0.9997
IMX $2.5624
ETC $33.6826
RNDR $9.0476
STX $3.0152
FIL $8.0739
MNT $1.3057
TAO $634.6650
NEAR $6.7707
HBAR $0.0996
ATOM $10.7689
VET $0.0473
OKB $56.7850
WIF $3.4067
FDUSD $1.0024
KAS $0.1425
MKR $3339.9801
PEPE $0.0000
GRT $0.3118
THETA $2.9461
INJ $31.7489
FET $2.5268
XLM $0.1299
XMR $133.8901
USDE $1.0008
  • Catalog
  • Blog
  • Tor Relay
  • Jabber
  • One-Time notes
  • Temp Email
  • What is TOR?
  • We are in tor
  • MAPS announces successful completion of phase III MDMA clinical trial for PTSD


    MAPS, the Multidisciplinary Association for the Study of Psychedelics, informed the press of the successful completion of the third and final phase of the association's clinical trial for MDMA. Thus, the research of the organization confirms the effectiveness of the use of this drug in the treatment of PTSD in its various forms and manifestations.

    This trial, called MAPP2, involved 100 volunteers formally diagnosed with PTSD. As in the case of the previous trial, the use of the substance helped most patients to ease the symptoms of the disease.

    In parallel, the organization continues trials to study the effectiveness of MDMA in the treatment of drug addiction, depressive and stress disorders, as well as dietary, water and anorexia disorders. In addition, the organization is testing psilocybin, which is also being studied as a treatment for PTSD and depression.

    Note that both of these substances are also now being actively studied by the US Sanitary Research Laboratory, whose representatives promise to present the final results of their clinical trials before the end of the year. The publication of these data, as well as certification by the US authorities, will not only make psilocybin and MDMA legal in the states, but also legitimize them as a medicine in the eyes of other countries of the world.

    Author DeepWeb
    Most of the criminal cryptocurrencies pass through the same exchanges
    GitHub revokes code signing certificates stolen when repositories hacked

    Comments 0

    Add comment